Cosette says Mayne backfilled sales estimates to meet $$70M forecast
Kicking off its appeal of a finding that it couldn’t walk away from a $672 million merger agreement with Mayne Pharma, US drug company Cosette has told a court that Mayne was not upfront about its financial position prior to the deal.
For information on rights and reprints, contact subscriptions@lawyerly.com.au
